Berlin, July 10, 2012 – Bayer HealthCare today announced the 2012 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the company awards a total of approximately 2.3 million USD in funding to 15 recipients in nine countries. BHAP is the largest program of its kind in hemophilia, funding innovative research and educational initiatives around the world. As such, BHAP is a key program in Hemophilia Solutions, Bayer’s program of commitment to research, treatment and education in hemophilia.
The 2012 announcement is especially meaningful, as it marks the 10th anniversary of BHAP and its resulting contributions to the global hemophilia community. Since its founding in 2002, BHAP has awarded more than 200 grants, totaling more than 24 million USD, to researchers and caregivers from 29 countries around the world. BHAP support has resulted in more than 360 scientific abstracts, publications and presentations by awardees.
“The scientists and caregivers we honor today are performing the research needed to develop, for example, improved hemophilia therapies,” said Prasad Mathew, Vice President, Global Medical Affairs Hematology, Bayer HealthCare. “They are laying the groundwork for greater understanding of many aspects of hemophilia, and I look forward to seeing the results of their valuable work in the future.”
BHAP awardees are selected by a global panel of distinguished hemophilia clinicians, researchers and caregivers. Awards are given in four categories; Special Project, Early Career Investigator, Fellowship Project and Caregiver. The full list of awardees and their respective project titles can be found at www.bayer-hemophilia-awards.com.
“Those receiving the BHAP award this year are an extraordinary group of researchers and caregivers. While the selection process is never easy, we are consistently impressed by the quality of the research. We are confident that this year’s winners will make meaningful advances to hemophilia research,” said Prof. Johannes Oldenburg, chairman of the BHAP Grants, Review and Awards Committee and Head of the Institute of Experimental Haematology and Transfusion Medicine at University Clinic Bonn.
BHAP is one example of Bayer’s commitment to expanding the scientific and clinical knowledge that improves patient care. BHAP research priorities include prophylaxis, impact of advancing age on hemophilia patients, treatment innovations, and the mechanism of action of clotting factor concentrates.
The 2012 BHAP award recipients were announced at the World Federation of Hemophilia (WFH) Congress in Paris.
About the Bayer Hemophilia Awards Program
The Bayer Hemophilia Awards Program (BHAP) supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training and other hemophilia care professionals, the program seeks to support the next generation of care and treatment options for people with hemophilia worldwide. For more information about BHAP, please visit www.bayer-hemophilia-awards.com.
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.
To learn more about hemophilia, please visit: www.bayerpharma.de/hemophilia
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
Find more information at www.bayerpharma.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
